Piribedil
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Piribedil
- Pharmacist Assessment Report
- Piribedil: From Parkinson Disease to Retinal Dystrophy with or without Extraocular Anomalies
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Piribedil: From Parkinson Disease to Retinal Dystrophy with or without Extraocular Anomalies
One-Sentence Summary
Piribedil is a dopamine agonist originally used to treat Parkinson disease and other parkinsonian disorders. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently no registered clinical trials and only 1 loosely related publication, so this prediction rests almost entirely on computation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson disease / parkinsonian disorder |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, piribedil is a D2/D3 dopamine receptor agonist with additional alpha-2 adrenergic antagonist activity. Its efficacy in Parkinson disease comes from replacing dopaminergic stimulation in the brain.
Dopamine signalling also takes part in normal retinal physiology, so a theoretical link to retinal disease is plausible. However, this link is indirect. The only publication retrieved discusses syncope in Kearns-Sayre syndrome, a mitochondrial disorder that includes retinopathy. It does not test piribedil or any other dopamine agonist in retinal dystrophy.
The high TxGNN score (0.9934) is a computational prediction without direct clinical support. It should be treated as a hypothesis to explore, not as evidence of benefit.
Other predictions in the top 5
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Paralysis agitans, juvenile, of Hunt | 0.9934 | L5 | Historical label that overlaps with the approved Parkinson disease indication, so it adds little new repurposing value |
| 3 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 0.9912 | L5 | No plausible mechanism from dopamine agonism to a structural developmental malformation |
| 4 | PLA2G6-associated neurodegeneration | 0.9907 | L5 | Could give limited symptomatic motor benefit only, with no effect on the underlying disease |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17086014 | 2006 | Review | The American Heart Hospital Journal | Pathophysiology and management of syncope in Kearns-Sayre syndrome, with a case of complete atrioventricular block in a 20-year-old woman. It does not study piribedil or retinal dystrophy treatment. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 215839 | Trivastal LA Tablet SR (Serdia Pharmaceuticals India Pvt Ltd) | Sustained-release tablet (strip of 10) | Not stated in the available data |
Safety Considerations
Please refer to the package insert for safety information.
No drug interaction records were found, and no contraindications were identified in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for retinal dystrophy has a high model score but no supporting trials and only one indirectly related publication, which does not test piribedil. The other top predictions are either already covered by the approved Parkinson indication or lack a plausible mechanism.
To proceed, the following is needed:
- Mechanism of action data for piribedil, and a clearer rationale for any effect on retinal dopaminergic pathways
- Preclinical or retinal-model studies testing dopamine agonists in retinal dystrophy
- The package insert (warnings, contraindications, approved indication text) to complete the safety screening, which is currently blocked
- Drug interaction and safety data relevant to the target population
- Route and formulation assessment for any ocular indication, since the only marketed form is an oral sustained-release tablet
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.